Megaloblastic Anemia Workup

  • Author: Paul Schick, MD; Chief Editor: Emmanuel C Besa, MD   more...
 
Updated: Feb 24, 2012
 

Approach Considerations

Workup for megaloblastic anemia may include a complete blood count (CBC) and peripheral smear; lactate dehydrogenase (LDH), indirect bilirubin, iron, and ferritin assays; tests for cobalamin deficiency (eg, serum cobalamin, Schilling test, protein-bound absorption test); tests for folate deficiency (eg, serum folate and red blood cell [RBC] folate); diagnostic imaging (for possible blind loop syndrome); and bone marrow aspiration and biopsy.

Next

Initial Studies

Initial studies include a complete blood cell (CBC) count, RBC indices, platelet count, a peripheral smear, differential WBC count, and a reticulocyte count.

A CBC and platelet count would confirm an anemia and pancytopenia that are characteristic of severe megaloblastosis. RBC indices (an elevated mean corpuscular volume) would indicate macrocytosis.

A peripheral smear would demonstrate macroovalocytes that are characteristic of megaloblastosis. They should be distinguished from macrocytes that are not oval and occur in liver disease, hemolytic anemia, and in patients with increased RBC production.

The smear might also reveal megaloblasts and hypersegmented neutrophils that contain 5 or more lobes. Normal neutrophils contain 3-4 lobes. The smear might demonstrate RBCs with multiple Howell-Jolly bodies that represent nuclear fragments.

Macrocytosis due to cobalamin or folate deficiencies may be masked in patients with iron deficiency. However, hypersegmentation of neutrophils can persist in iron deficiency.

The reticulocyte count can be low despite hemolysis. This dissociation is characteristic of intramedullary hemolysis.

Note the image below.

Megaloblastic anemia. View of red blood cells Megaloblastic anemia. View of red blood cells

Lactate hydrogenase (LDH) and indirect bilirubin levels are increased due to intramedullary hemolysis. The LDH is usually markedly increased in severe megaloblastic anemia.

Previous
Next

Tests to Diagnose Cobalamin and Folate Deficiencies

Serum vitamin B-12 and RBC folate levels

Blood should be drawn prior to transfusions, meals, and therapy to achieve accurate results. Serum folate values are affected by meals and can be become normal after a single hospital meal. In contrast, RBC folate levels are not affected by diet since folate content is established early in RBC development. However, RBC folate is less sensitive for detecting a deficiency than serum folate. Serum for folate and cobalamin should be frozen and stored prior to meals or therapy if the tests cannot be performed within a reasonable timeframe. Serum vitamin B-12 and folate levels are usually low in cobalamin and folate deficiency but false positive and negatives can occur.

Serum homocysteine and methylmalonic acid levels

The former is elevated in both cobalamin and folate deficiencies, while the later is elevated only in cobalamin deficiency. These tests can be used if the clinical presentation and serum vitamin B-12 and folate levels are ambiguous.

Parietal cell and intrinsic factor antibodies

The former is present in 90% of patients with pernicious anemia, but it can also is found in thyroid disease and other autoimmune disorders. Anti-intrinsic factor antibodies (type I and II) are highly specific for pernicious anemia. However, these tests are not commonly ordered.

Schilling test

A Schilling test (a radiometric test) is given in 3 parts and can distinguish between pernicious anemia, a failure of cobalamin uptake in the terminal ileum, and a blind loop syndrome. The test may not be available at many hospitals. The 3 parts to the Schilling test are as follows:

  1. First, radioactive cyanocobalamin is given orally and its urinary secretion is measured to estimate the ability to take up cobalamin. Low secretion suggests either pernicious anemia, an abnormality in the terminal ileum, or a blind loop syndrome.
  2. The second part is performed in the same manner, except that intrinsic factor is given orally along with radioactive cyanocobalamin. If intrinsic factor restores cobalamin uptake, the patient most likely has pernicious anemia. If not, an abnormality in the terminal ileum or a blind loop syndrome might be present.
  3. In the third phase, the patient is treated with antibiotics before the administration of radioactive cyanocobalamin. If antibiotics restore cobalamin uptake, the patient most likely has a blind loop syndrome.

Problems

The main difficulty with the Schilling test is inadequate collection of urine samples in patients who are either noncompliant or have renal failure. Another issue is that severe folate deficiency affects ileal mucosa and therefore can block cobalamin uptake. Therefore, a Schilling test would be more reliable after patients have been treated with folate and cobalamin so that the ileal mucosa’s ability to take up cobalamin has been restored. A Schilling test can be performed in patients treated with cobalamin.

Previous
Next

A Short Trial of Cobalamin Therapy

This is useful if the clinical presentation and results from routine diagnostic tests are ambiguous.

Serum ferritin and iron studies are performed. It is important to establish baseline iron levels prior to treatment since iron is consumed when patients are treated with cobalamin and folate. Therefore, the baseline value can be helpful in predicting the need for iron therapy in patients who are being treated with cobalamin and folate.

Previous
Next

Bone Marrow and Peripheral Smear Morphology

A bone marrow aspiration is useful to confirm the diagnosis, to rule out myelodysplasia, and to assess the iron stores. The bone marrow is hypercellular with erythroid hyperplasia. Erythroid precursors have megaloblastic features in that they are larger than normoblastic cells and they have immature nuclear development. Megaloblastic changes are most prominent in more mature RBC precursors. Cytoplasmic maturation is normal, but nuclear remnants, Howell-Jolly bodies, may be present in the cytoplasm. Giant bands (neutrophils) can be present. Megakaryocytes may be large and hyperlobulated.

Bone marrow megaloblastic changes are reversed within 12 hours after treatment with cobalamin or folate, and bone marrow morphology appears to be normal within 2-3 days. Therefore, a bone marrow aspiration should be performed as soon as possible and preferably before therapy.

With peripheral smears, macroovalocytes and hypersegmented neutrophils are present. Megaloblasts may be present. RBCs may have multiple Howell-Jolly bodies in their cytoplasm. Pancytopenia is a common finding.

Previous
Next

Other Studies

Abdominal radiographs, upper and lower gastrointestinal series, and computed tomography (CT) scans may be useful for detecting and evaluating strictures and other gastrointestinal tract abnormalities that could cause a blind loop syndrome.

Other tests that may be considered include the following:

  • With cobalamin deficiency: Tests and diagnostic studies can be performed for the detection and evaluation of other autoimmune disorders. Regional ileitis, fish tapeworm infection, Zollinger-Ellison syndrome, and pancreatitis should be ruled out.
  • With folate deficiency: Diagnostic studies can be performed to detect malnutrition, sprue, chronic hemolysis, and exfoliative dermatitis.
  • Tests relevant for the diagnosis and evaluation of inborn errors that cause or are associated with cobalamin or folate deficiency may be warranted.
Previous
 
 
Contributor Information and Disclosures
Author

Paul Schick, MD  Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Hematology, International Society on Thrombosis and Haemostasis, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Specialty Editor Board

Thomas H Davis, MD, FACP  Associate Professor, Fellowship Program Director, Department of Internal Medicine, Section of Hematology/Oncology, Dartmouth Medical School

Thomas H Davis, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Education, American College of Physicians, New Hampshire Medical Society, Phi Beta Kappa, and Society of University Urologists

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ronald A Sacher, MB, BCh, MD, FRCPC  Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Clinical and Climatological Association, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society of Blood Transfusion, International Society on Thrombosis and Haemostasis, and Royal College of Physicians and Surgeons of Canada

Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

Chief Editor

Emmanuel C Besa, MD  Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Clinical Oncology, American Society of Hematology, and New York Academy of Sciences

Disclosure: Nothing to disclose.

References
  1. Hoffman R, Benz EJ, Furie B, Shattil SJ. Hematology: Basic Principles and Practice. Philadelphia, Pa: Churchill Livingstone; 2009.

  2. Wang YH, Yan F, Zhang WB, Ye G, Zheng YY, Zhang XH, et al. An investigation of vitamin B12 deficiency in elderly inpatients in neurology department. Neurosci Bull. Aug 2009;25(4):209-15. [Medline].

  3. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw Hill; 2001.

  4. Dali-Youcef N, Andres E. An update on cobalamin deficiency in adults. QJM. Jan 2009;102(1):17-28. [Medline].

  5. Filioussi K, Bonovas S, Katsaros T. Should we screen diabetic patients using biguanides for megaloblastic anaemia?. Aust Fam Physician. May 2003;32(5):383-4. [Medline].

  6. Gomber S, Dewan P, Dua T. Homocystinuria: a rare cause of megaloblastic anemia. Indian Pediatr. Sep 2004;41(9):941-3. [Medline].

  7. Borgna-Pignatti C, Azzalli M, Pedretti S. Thiamine-responsive megaloblastic anemia syndrome: long term follow-up. J Pediatr. Aug 2009;155(2):295-7. [Medline].

  8. Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL. Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, infant, and child development. Food Nutr Bull. Jun 2008;29(2 Suppl):S101-11; discussion S112-5. [Medline].

  9. U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. May 5 2009;150(9):626-31. [Medline].

  10. Dary O. Nutritional interpretation of folic acid interventions. Nutr Rev. Apr 2009;67(4):235-44. [Medline].

  11. Lawrence MA, Chai W, Kara R, Rosenberg IH, Scott J, Tedstone A. Examination of selected national policies towards mandatory folic acid fortification. Nutr Rev. May 2009;67 Suppl 1:S73-8. [Medline].

  12. Varela-Moreiras G, Murphy MM, Scott JM. Cobalamin, folic acid, and homocysteine. Nutr Rev. May 2009;67 Suppl 1:S69-72. [Medline].

  13. Mayo Clinic. Folate dosing. Mayoclinic.com. Available at http://www.mayoclinic.com/health/folate/NS_patient-folate/DSECTION=dosing. Accessed August 5, 2011.

Previous
Next
 
Megaloblastic anemia. View of red blood cells
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.